Details

Autor(en) / Beteiligte

• Grim, Shellee A.
• Rene, Lisa
• Gupta, Sandeep
• Clark, Nina M.

Titel

Safety of linezolid in patients with baseline thrombocytopenia

Ist Teil von

• Journal of antimicrobial chemotherapy, 2008-10, Vol.62 (4), p.850-851

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2008

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Thrombocytopenia (TCP) is a known risk factor (RF) associated with linezolid, most often manifesting after 2 weeks of therapy. The rate of TCP was 2.4% (range 0.3% to 10%) in clinical trials;1 however, post-marketing surveillance revealed an incidence of TCP [defined variably as platelet (PLT) counts of [less than or equal to] 100 000 to [less than or equal to]150 000/mcL] from 6% to 32%.3-6 The risk of severe TCP and bleeding complications (BCs) in patients administered linezolid in the setting of baseline (BL) TCP is unknown. Populations with high rates of drug-resistant Gram-positive infections are often cytopenic due to underlying diseases and/or therapeutic modalities. We sought to determine the effect of linezolid on PLT counts and bleeding risk in these patients.